Total Payments
$6,953
2024 Payments
$895.67
Companies
58
Transactions
155
Medicare Patients
12,707
Medicare Billing
$3.6M
Payment Breakdown by Category
Food & Beverage$6,831 (98.2%)
Education$122.55 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,831 | 150 | 98.2% |
| Education | $122.55 | 5 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $625.51 | 5 | $0 (2024) |
| Ethicon US, LLC | $603.29 | 5 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $359.68 | 20 | $0 (2024) |
| Foundation Medicine, Inc. | $306.33 | 1 | $0 (2017) |
| Exelixis Inc. | $282.39 | 4 | $0 (2022) |
| DAVOL INC. | $260.61 | 2 | $0 (2019) |
| Pacira Pharmaceuticals Incorporated | $241.68 | 2 | $0 (2024) |
| Allergan Inc. | $218.61 | 3 | $0 (2019) |
| Gilead Sciences, Inc. | $199.73 | 11 | $0 (2024) |
| Fresenius Kabi USA, LLC | $178.35 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $895.67 | 36 | Novartis Pharmaceuticals Corporation ($157.36) |
| 2023 | $1,164 | 44 | Novartis Pharmaceuticals Corporation ($202.32) |
| 2022 | $1,513 | 35 | Celgene Corporation ($585.34) |
| 2021 | $684.83 | 10 | Ethicon US, LLC ($236.16) |
| 2020 | $316.02 | 3 | TELA Bio, Inc. ($145.97) |
| 2019 | $898.99 | 8 | Exelixis Inc. ($253.94) |
| 2018 | $526.25 | 10 | Novo Nordisk Inc ($133.02) |
| 2017 | $955.43 | 9 | Foundation Medicine, Inc. ($306.33) |
All Payment Transactions
155 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.03 | General |
| 12/04/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.33 | General |
| 10/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.69 | General |
| 10/11/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Hematology | ||||||
| 09/25/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $18.68 | General |
| 09/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.00 | General |
| 09/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $27.01 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.24 | General |
| 08/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Pacira Pharmaceuticals Incorporated | Exparel (Drug) | Food and Beverage | In-kind items and services | $116.71 | General |
| Category: Pain Management | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Oncology | ||||||
| 05/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 2,827 | 46,737 | $2.7M | $542,247 |
| 2022 | 60 | 2,934 | 58,910 | $3.9M | $831,369 |
| 2021 | 61 | 3,271 | 67,604 | $4.1M | $946,002 |
| 2020 | 67 | 3,675 | 77,643 | $5.4M | $1.2M |
Total Patients
12,707
Total Services
250,894
Medicare Billing
$3.6M
Procedure Codes
243
All Medicare Procedures & Services
243 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 4,200 | $572,800 | $181,197 | 31.6% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 52 | 75 | $360,150 | $82,549 | 22.9% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 20 | 1,710 | $401,040 | $57,412 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 256 | 575 | $211,600 | $51,601 | 24.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,260 | $83,040 | $23,113 | 27.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 19 | 8,805 | $176,100 | $20,743 | 11.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 80 | 165 | $116,655 | $15,654 | 13.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 49 | 58 | $61,886 | $9,833 | 15.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 61 | $30,256 | $8,219 | 27.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 290 | 903 | $18,060 | $7,585 | 42.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 275 | 717 | $45,888 | $7,413 | 16.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 56 | 80 | $52,560 | $7,074 | 13.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 281 | 824 | $29,664 | $6,264 | 21.1% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 11 | 18 | $30,996 | $5,986 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $27,120 | $5,961 | 22.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 89 | 117 | $36,621 | $5,613 | 15.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 73 | $18,031 | $4,421 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 73 | $18,250 | $4,062 | 22.3% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 11 | 665 | $77,140 | $2,961 | 3.8% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 50 | 63 | $51,723 | $2,956 | 5.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 73 | 250 | $27,000 | $2,922 | 10.8% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 80 | 131 | $16,768 | $2,655 | 15.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 51 | $17,544 | $2,476 | 14.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 44 | $9,284 | $2,413 | 26.0% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 55 | 14,400 | $28,800 | $2,260 | 7.8% |
About Dr. Carlos Taboada, MD
Dr. Carlos Taboada, MD is a Medical Oncology healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174565089.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Taboada, MD has received a total of $6,953 in payments from pharmaceutical and medical device companies, with $895.67 received in 2024. These payments were reported across 155 transactions from 58 companies. The most common payment nature is "Food and Beverage" ($6,831).
As a Medicare-enrolled provider, Taboada has provided services to 12,707 Medicare beneficiaries, totaling 250,894 services with total Medicare billing of $3.6M. Data is available for 4 years (2020–2023), covering 243 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Plano, TX
- Active Since 06/12/2006
- Last Updated 02/04/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1174565089
Products in Payments
- Pomalyst (Drug) $603.82
- FOUNDATIONONE (Device) $306.33
- Cabometyx (Drug) $282.39
- Exparel (Drug) $241.68
- ECHELON ENDOPATH (Device) $239.10
- Echelon; Endopath (Device) $227.21
- STRATTICE (Device) $218.61
- Smoflipid (Drug) $178.35
- SIR-Spheres Microspheres (Device) $151.68
- HEMOBLAST BELLOWS (Device) $148.82
- Ovitex (Device) $145.97
- Echelon Flex (Device) $136.98
- PHASIX (Device) $135.62
- Sonicision (Device) $133.88
- Ozempic (Drug) $133.02
- KISQALI (Drug) $130.80
- Doptelet (Drug) $129.99
- GATTEX (Drug) $127.96
- Axonics r-SNM System (Device) $126.68
- Trulance (Drug) $125.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Plano
Dr. Christopher Stokoe, Md, MD
Medical Oncology — Payments: $97,483
Medical Oncology $97,483
Dr. Scott Stone, Md, MD
Medical Oncology — Payments: $46,037
Medical Oncology $46,037
Dr. Asha Karippot, Md, MD
Medical Oncology — Payments: $5,084
Medical Oncology $5,084
Dr. Charles Connor, M.d, M.D
Medical Oncology — Payments: $1,694
Medical Oncology $1,694
Dr. Khusroo Qureshi, M.d, M.D
Medical Oncology — Payments: $860.81
Medical Oncology $860.81